Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
&NA; Alzheimer's disease (AD) is a neurodegenerative disorder, characterized by progressive dementia, neuroinflammation and the accumulation of intracellular neurofibrillary tangles and extracellular plaques. The etiology of AD is unclear, but is generally attributed to four leading hypotheses: (i) abnormal folding and aggregation of amyloid‐&bgr; (A&bgr;)/tau proteins (ii) activation of the innate immune system, (iii) mitochondrial dysfunction, and (iv) oxidative stress. To date, therapeutic strategies have largely focused on A&bgr;‐centric targets; however, the repeated failure of clinical trials and the continued lack of a disease‐modifying therapy demand novel, multifaceted approaches. Natural products are common molecular platforms in drug development; in AD, compounds from the plant phenylpropanoid metabolic pathway have yielded promising associations. Herein, we review developments in the pathogenesis of AD and the metabolism of phenylpropanoids in plants. We further discuss the role of these metabolites as relevant to the four leading mechanisms of AD pathogenesis, and observe multiple protective effects among phenylpropanoids against AD onset and progression. HighlightsAlzheimer's disease (AD) originates from multiple intertwined mechanisms.Phenylpropanoids are plant metabolites with a variety of bioactive interactions.Their effect on A&bgr;/tau, inflammation, oxidative stress & mitochondria are reviewed.Phenylpropanoids may be a promising candidate for therapeutic intervention in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Harman, D. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.11.7124 · Cited by 1,915
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid Fibrils
Petkova, A. T., Leapman, R. D., Guo, Z., Yau, W.-M., Mattson, M. P., & Tycko, R. (2005) · Science · doi:10.1126/science.1105850 · Cited by 1,687
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“…release of proinflammatory signalling can also recruit and activate additional glial cells, triggering an immune cascade and an uncontrolled feed-forward cycle, which if unabated, can lead to broad neural damage (Gao and Hong, 2008; Griffin et al., 1995; Hickman et al., 2008; Jimenez et al., 2008).”
BackgroundAstrocytes are active players in cerebral innate immunity
Farina, C., Aloisi, F., & Meinl, E. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.01.005 · Cited by 1,304 · cited 1×
“The stilbene resveratrol, found in grapes and red wine, aids the degradation of Aβ via a proteasome-dependent mechanism (Marambaud et al., 2005), while also preventing Aβ fibril formation in vitro (Feng et al., 2009).”
ABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) · Science · doi:10.1126/science.1091230 · Cited by 1,303
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287 · cited 1×
“However, activated microglia and astrocytes release a variety of proinflammatory cytokines (Glass et al., 2010; Griffin et al., 1998; McDonald et al., 1997; McGeer and McGeer, 1995, 2001), which can create regions of intense inflammatory stress, damaging the function and structure of neurons.”
Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254 · cited 1×
“Curcumin has been shown to be a potent inhibitor of Aβ fibrillization (Kim et al., 2005; Ono et al., 2004), Aβ oligomerization (Yang et al., 2005), and promotes destabilization of pre-existing Aβ deposits (Lim et al., 2001; Yang et al., 2005).”
BackgroundImpaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease
Wang, X., Su, B., Lee, H.-G., Li, X., Perry, G., Smith, M. A., & Zhu, X. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1357-09.2009 · Cited by 1,224
Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., & Reddy, P. H. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl066 · Cited by 1,104 · cited 2×
“There is evidence suggesting that intracellular Aβ and tau accumulate and interact with the mitochondria, disrupting the function of critical proteins (Casley et al., 2002; Gibson et al., 1988; Lustbader et al., 2004; Manczak et al., 2006; Moreira et al., 2010; Park et al., 2004).”
BackgroundBitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., & Sinclair, D. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205670200 · Cited by 1,002 · cited 1×
“In plants, phenylpropanoids act as direct antioxidants, scavenging and quenching free radicals by donating protons or electrons from the phenol moiety (Bors et al., 1990; Sarkar et al., 2012).”
Mitochondria and Mitochondrial Cascades in Alzheimer’s disease
Swerdlow, R. H. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170585 · Cited by 850 · cited 2×
““The mitochondrial cascade hypothesis”, therefore suggests that mitochondrial dysfunction may play a central role in initiating key AD pathologies, including Aβ production, tau hyperphosphorylation, synaptic loss and neurodegeneration (Onyango et al., 2016; Swerdlow, 2018; Swerdlow and Khan, 2004).”
Opposing activities protect against age-onset proteotoxicity
Cohen, E., Bieschke, J., Perciavalle, R. M., Kelly, J. W., & Dillin, A. (2006) · Science · doi:10.1126/science.1124646 · Cited by 843
A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease
Swerdlow, R. H., & Khan, S. M. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.12.045 · Cited by 758
Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology
Moreira, P. I., Carvalho, C., Zhu, X., Smith, M. A., & Perry, G. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.006 · Cited by 734
Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., Townsend, K., Zeng, J., Morgan, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1521-05.2005 · Cited by 713
Atwood, C. S., Scarpa, R. C., Huang, X., Moir, R. D., Jones, W. D., Fairlie, D. P., Tanzi, R. E., & Bush, A. I. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751219.x · Cited by 641
Tau protein kinases: Involvement in Alzheimer's disease
Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., & Terro, F. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.003 · Cited by 631
Alzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549
Mechanisms of Aβ Clearance and Degradation by Glial Cells
Ries, M., & Sastre, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00160 · Cited by 527 · cited 1×
“These cells serve important developmental and maintenance roles, and are thus initially activated as a neuroprotective response to early AD pathologies (Barger and Harmon, 1997; Farina et al., 2007; Frautschy et al., 1998; Guillot-Sestier et al., 2015; Ries and Sastre, 2016).”
Quercetin increases brain and muscle mitochondrial biogenesis and exercise tolerance
Davis, J. M., Murphy, E. A., Carmichael, M. D., & Davis, B. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90925.2008 · Cited by 486
Drug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459
Alzheimer Disease and Oxidative Stress
Perry, G., Cash, A. D., & Smith, M. A. (2002) · BioMed Research International · doi:10.1155/s1110724302203010 · Cited by 455
Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
Rich, J. B., Rasmusson, D. X., Folstein, M. F., Carson, K. A., Kawas, C., & Brandt, J. (1995) · Neurology · doi:10.1212/wnl.45.1.51 · Cited by 446
Hollman, P. C. H., Cassidy, A., Comte, B., Heinonen, M., Richelle, M., Richling, E., Serafini, M., Scalbert, A., Sies, H., & Vidry, S. (2011) · The Journal of Nutrition · doi:10.3945/jn.110.131490 · Cited by 406 · cited 1×
“quenching has been disputed (Hollman et al., 2011), phenylpropanoids are also known to favourably regulate expression of ROS-removing”
Jimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383
Tau Aggregation and Its Interplay with Amyloid-β
Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359 · cited 1×
“However, these efforts have yet to yield an effective therapy, possibly as tau's place in AD etiology and its synergism with Aβ remain ambiguous (Bakota and Brandt, 2016; Khan and Bloom, 2016; Nisbet et al., 2015).”
BackgroundAbnormalities of mitochondrial enzymes in Alzheimer disease
Gibson, G. E., Sheu, K.-F. R., & Blass, J. P. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050099 · Cited by 345
Tamagno, E., Parola, M., Bardini, P., Piccini, A., Borghi, R., Guglielmotto, M., Santoro, G., Davit, A., Danni, O., Smith, M. A., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02895.x · Cited by 324 · cited 1×
“, 2000), increase the expression of β-secretase (Tamagno et al., 2005) and increase aberrant tau phosphorylation (Lovell et al.”
Mitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies
Onyango, I. G., Dennis, J., & Khan, S. M. (2016) · Aging and Disease · doi:10.14336/ad.2015.1007 · Cited by 260
Metal-associated amyloid-β species in Alzheimer's disease
Pithadia, A. S., & Lim, M. H. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.01.016 · Cited by 259 · cited 2×
“redox cycling that leads to the production of ROS (Atwood et al., 2000; Bush, 2013; Pithadia and Lim, 2012; Savelieff et al., 2013).”
Wang, J.-Y., Wen, L. L., Huang, Y.-N., Chen, Y.-T., & Ku, M.-C. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778343109 · Cited by 250
Müller, W. E., Eckert, A., Kurz, C., Eckert, G. P., & Leuner, K. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8141-5 · Cited by 243
Candelario-Jalil, E., de Oliveira, A. C. P., Gräf, S., Bhatia, H. S., Hüll, M., Muñoz, E., & Fiebich, B. L. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-25 · Cited by 223
Oxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Drug development for Alzheimer's disease: where are we now and where are we headed?
Sabbagh, M. N. (2009) · The American journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147
Memantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias
Molinuevo, J. L., Lladó, A., & Rami, L. (2005) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/153331750502000206 · Cited by 125
Biala, A., Tauriainen, E., Siltanen, A., Shi, J., Merasto, S., Louhelainen, M., Martonen, E., Finckenberg, P., Muller, D. N., & Mervaala, E. (2010) · Blood Pressure · doi:10.3109/08037051.2010.481808 · Cited by 97 · cited 2×
“…via activation of the ‘Kelch ECH associating protein’ (Keap1), ‘NF-E2-related factor 2’ (Nrf2) and ‘antioxidant response elements’ (ARE) signalling pathways (Biasibetti et al., 2013; Moskaug et al., 2005; Tsuji et al., 2013; Bahia et al., 2008; Hernandez-Montes et al., 2006; Lim et al., 2014).”
Polidori, M., & Nelles, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660706 · Cited by 69
Cited by
Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update
Cenini, G., & Voos, W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00902 · Cited by 257
Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases
Stanga, S., Caretto, A., Boido, M., & Vercelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103719 · Cited by 90
Dual Role of Phenyl Amides from Hempseed on BACE 1, PPARγ, and PGC-1α in N2a-APP Cells
Rea Martinez, J., Šelo, G., Fernández-Arche, M. Á., Bermudez, B., & García-Giménez, M. D. (2021) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00435 · Cited by 9
Metadata
- Authors
- Kolaj, I., Imindu Liyanage, S., & Weaver, D. F.
- Venue
- Neurochemistry International
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 120
- Pages
- 99-111
- ISSN
- 0197-0186 (ISSN-L)
- OpenAlex
- W2887009692
- Cited by
- 39
- References
- 46
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.